• Vaccine Name: T. cruzi vaccine encoding recombinant enolase from H8 strain
• Target Pathogen: Trypanosoma cruzi
• Target Disease: Chagas disease
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Antigen: Recombinant enolase from T. cruzi H8 strain (Arce-Fonseca et al., 2018)
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000142
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000139
• Immunization Route: Intraperitoneal injection (i.p.)
• Description: Vaccine encoding rTcENO (recombinant enloase) from the H8 strain emulsified in Freund's Complete Adjuvant and Freund's Incomplete Adjuvant (Arce-Fonseca et al., 2018)

Mouse Response

• Host Strain: BALB/c
• Host age: 6-8 weeks old
• Host gender: Female
• Vaccination Protocol: All mice were randomly assigned into control or vaccinated groups of eight mice each in two independent experiments. The mice were immunized by intraperitoneal (i.p.) injection with 10 μg of the recombinant protein (rTcENO) emulsified in Freund's complete adjuvant (CFA) (Sigma) and boosted twice with 10 μg of the rTcENO in Freund's incomplete adjuvant (IFA) every 2 weeks. were randomly assigned into control or vaccinated groups of eight mice each in two independent experiments. The mice were immunized by intraperitoneal (i.p.) injection with 10 μg of the recombinant protein (rTcENO) emulsified in Freund's complete adjuvant (CFA) (Sigma) and boosted twice with 10 μg of the rTcENO in Freund's incomplete adjuvant (IFA) every 2 weeks. (Arce-Fonseca et al., 2018)
• Immune Response: The immunizations with rTcENO induced a significant production of IgGs against the rTcENO antigen seven days after the last immunization. Antigen-specific isotypes of immunoglobulins in the sera of immunized animals with rTcENO revealed high levels of IgG1>IgG2b>IgG2a, indicating that this antigen induced a mixed Th1-/Th2-like immune response. The mice immunized with rTcENO exhibited high titers of antibodies compared to the control groups inoculated with PBS or pBK-CMV. (Arce-Fonseca et al., 2018)
• Challenge Protocol: Challenged the immunized mice with a lethal dose of T. cruzi. The mice immunized with rTcENO showed typical immunoglobulins for Th1/Th2 immune responses, a significant reduction in the level of parasite burden in the blood, and 75% survival rate in comparison to the control groups. Moreover, the detection of IFN-γ, TNF (alpha and beta), and IL-2, but not IL-4, showed a polarized Th1 immune response when mice were challenged with T. cruzi. (Arce-Fonseca et al., 2018)